|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.17/-1.37
|
企业价值
264.57M
|
资产负债 |
每股账面净值
1.29
|
现金流量 |
现金流量率
0.40
|
损益表 |
收益
755.00K
|
每股收益
0.16
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/12 03:17 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications. |